Medtronic Plc Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Medtronic Plc on July 10, 2019. The filing discloses the early results and pricing of tender offers for various series of senior notes issued by the Company's subsidiaries, as well as a notice of redemption for remaining notes not tendered. The transactions follow the closing of a registered public offering of €5.0 billion in senior notes on July 2, 2019.
Key Financial Metrics and Debt Transactions
- Total Debt Repurchase: The Company announced the purchase of $5.171 billion in aggregate principal amount of senior notes.
- Tender Offer Proceeds: $4.638 billion was purchased pursuant to the Tender Offers.
- Redemption Notes: $533 million in notes were subject to mandatory redemption ($249.8 million of 4.125% Senior Notes due 2021 and $283.6 million of 3.125% Senior Notes due 2022).
- Liquidity Impact: The Company expects these transactions to be effectively leverage neutral.
- Interest Expense (Non-GAAP):
- Q1 FY20: Expected to remain in the previously disclosed range of $200 million to $210 million.
- Q2-Q4 FY20: Revised expectation of $170 million to $180 million per quarter.
Material Changes and Outlook
The refinancing transactions are expected to reduce non-GAAP interest expense in the second, third, and fourth quarters of fiscal year 2020. This reduction is anticipated to be partially offset by a slight increase in U.S. tax expense on a pre-tax basis. Management stated that the financial benefits provide comfort regarding the upper end of the current fiscal year 2020 earnings per share (EPS) guidance range of $5.44 to $5.50.
The Company plans to update its EPS guidance upon the release of first-quarter earnings results, currently expected on August 20, 2019. The redemption date for the Redemption Notes is set for August 9, 2019.
Risks and Contingencies
Forward-looking statements in this report are subject to risks and uncertainties, including:
- Acceptance levels of tendered notes and the successful consummation of the Tender Offers.
- Competitive factors and regulatory challenges in the medical technology industry.
- General economic conditions and difficulties inherent in product development and manufacturing.
- The inherent uncertainty in reconciling forward-looking non-GAAP interest expense due to potential fees and costs associated with the tender offers.
Investor Verification Checklist
- Verify the final settlement of the Tender Offers and the exact amount of debt retired versus the $5.171 billion target.
- Monitor the August 20, 2019 earnings release for the updated fiscal year 2020 EPS guidance.
- Review the actual Q1 FY20 interest expense to confirm it aligns with the $200 million to $210 million expectation.
- Assess the impact of the slight increase in U.S. tax expense on net income in Q2-Q4 FY20.
- Confirm the execution of the August 9, 2019 redemption for the $533 million in Redemption Notes.